share_log

Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $13

Benzinga Real-time News ·  Jan 24, 2023 08:57

Morgan Stanley analyst Matthew Harrison maintains Innoviva (NASDAQ:INVA) with a Underweight and lowers the price target from $14 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment